Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol

Abstract Background With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lionnel Geoffrois, Alexandre Harlé, Nassim Sahki, Aleksandra Sikanja, Florence Granel-Brocard, Alice Hervieu, Laurent Mortier, Géraldine Jeudy, Catherine Michel, Charlée Nardin, Cécile Huin-Schohn, Jean-Louis Merlin
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-06-01
coleção:	BMC Cancer
Assuntos:	Circulating tumor DNA Melanoma Adjuvant therapy Immunotherapy Kinase inhibitors
Acesso em linha:	https://doi.org/10.1186/s12885-023-11029-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!